Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: osteoporosis

Improve RA Care with Vitamin D

Dewan K. Fahima, DO, & Rafah Salloum, MD  |  November 16, 2015

Background Autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythema­tous, occur when the body attacks its own tissue because it cannot differentiate between self and non-self. This is mainly through deregulation of the immune system. Vitamin D has been known to play a critical role in bone mineralization and bone health. Activated vitamin…

Filed under:ConditionsPractice SupportRheumatoid Arthritis Tagged with:patient carePractice ManagementRARheumatoid arthritisTreatmentVitamin D

Fellows’ Forum Case Report: Palmar Fasciitis & Polyarthritis Syndrome

Naveen Raj, DO, MPH, Marc Kesselman, DO, & Barry Waters, MD  |  November 16, 2015

Case report: A 78-year-old Caucasian female presented to our outpatient rheumatology clinic with pain in her bilateral shoulders, hands and knees that began suddenly one month earlier. She admitted to stiffness in her hands lasting several hours, and expressed an inability to extend her fingers. She denied fever, rashes, jaw claudication, headache or visual changes….

Filed under:ConditionsOther Rheumatic ConditionsSoft Tissue Pain Tagged with:ClinicalDiagnosisFellowsFellows Forumhandpalmar fasciitispatient carepolyarthritisrheumatologistsymptom

Bone Turnover Markers Show Link to Iliac Histomorphometry in Older Women

Reuters Staff  |  November 12, 2015

NEW YORK (Reuters Health)—Although histomorphometry of iliac bone gives precise results, bone turnover markers provide a better reflection of the overall skeleton in untreated postmenopausal osteoporotic women, according to French researchers. Bone histomorphometry allows study of bone remodeling at the basic structural unit level, Dr. Pascale Chavassieux and colleagues at the University of Lyon note…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:boneIliac HistomorphometryOsteoporosispostmenopauseWomen

Researchers Identify Molecule That Promotes Osteogenesis

Lara C. Pullen, PhD  |  October 19, 2015

New insights into bone cell biology—including the identification of parbendazole, a bone anabolic compound that promotes bone formation—may lead to better treatments for osteoporosis…

Filed under:Conditions

Arthritis Power App Can Help Patients Monitor Symptoms, Improve Office Visits

Linda Childers  |  October 14, 2015

For the past 16 years, the website, creakyjoints.org, founded by arthritis patient Seth Ginsberg and social entrepreneur Louis Tharp, has offered arthritis patients and their families a safe online community where they can receive meaningful support and education. In March, the online portal added a new initiative—Arthritis Power, the first-ever patient-led, patient-generated, app-based research registry…

Filed under:AppsConditionsPractice SupportRheumatoid ArthritisTechnologyTechnology Tagged with:appsArthritispatient carephysicianPROsRheumatoid arthritisrheumatologysymptomsTechnologyTreatment

FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning

Michele B. Kaufman, PharmD, CGP, RPh  |  October 14, 2015

The U.S. Food and Drug Administration (FDA) has toughened the existing warnings for nonsteroidal anti-inflammatory drugs (NSAIDs) due to their stroke and myocardial infarction (MI) risk increase.1 Due to a continual review of these products, FDA is requiring label updates for all prescription NSAIDs. Over-the-counter (OTC) NSAIDs already list the increased risk of MI and…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:abaloparatideadverse eventsanti-inflammatoryclinical trialsdrugFDAMIMyocardial infarctionnonsteroidal anti-inflammatory drugsNSAIDsoutcomeResearchrheumatologyriskSafetystroketofacitinib citrate

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  October 13, 2015

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2015

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:combination therapyFDAFood and Drug AdministrationGolimumabInjectionMental HealthMethotrexateOsteoporosispostmenopauseromosozumab

Vitamin D in Rheumatology: Cause and Effect Unclear

Vanessa Caceres  |  September 15, 2015

The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. Vitamin…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:ClinicalOsteoporosisOutcomespatient carerheumatologyTreatmentVitamin D

EULAR 2015: Role of ACPA Positivity in Osteoarthritis

Thomas R. Collins  |  September 15, 2015

ROME, Italy—The role of ACPA positivity in osteoarthritis is coming more into focus, with results from recent studies by researchers in Germany showing that ACPA positivity apparently works in concert with rheumatoid factor positivity to enhance bone erosion and that ACPA-positive patients show signs of bone erosion before they have clinical signs of arthritis. The…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACPAImmunologyOAOsteoarthritispatient careTreatment

  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 58
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences